MAY 2023LIFE SCIENCES REVIEW8IN MY OPINIONBy Shola Oyewole, CIO, United Therapeutics Corporation [NASDAQ:UTHR]IADVANCED THERAPIES FOR PATIENTS SUFFERING FROM PAHShola Oyewoleam an information systems professional of 30 years, having worked in several industries including technology, education, non-profit, government, news media, and consulting. I currently serve as CIO for United Therapeutics (UT), a biotechnology company that is focused on the development of therapies for patients suffering from Pulmonary Arterial Hypertension (PAH), a life-threatening disease. Currently there is no cure for PAH, but UT has developed several drug therapies that treat the disease.I joined UT in 2000, and have helped grow the company to over $1.4 billion in annual revenue and more than 700 employees. This has been an exciting journey, both as it relates to the success of the company and the evolution of technology.Over the past 10 years, my focus has been on "keeping the lights on" through business process improvement: implementing ERP for finance and supply chain management, deploying solutions meeting good manufacturing practices to run UT's manufacturing and regulatory processes, user training, distributed computing via virtualization, thin-apping, business continuity planning, collaboration solutions, and rapid Cloud adoption. This is not to mention, fully leveraging the capabilities of the Internet.My role as CIO has evolved from Information
< Page 7 | Page 9 >